RxDoctor Payments DataLook up a doctor →

Maribel Cotto, MD

Hematology & Oncology · Caguas, PRNPI 1730348384

Payments from drug & device makers

$22,456in general payments, 2019–2025

Across 1,003 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$4K
  • AstraZeneca$2K
  • Amgen$2K
  • Johnson & Johnson$1K
  • Novartis$1K
  • Genentech USA, Inc.$1K
  • plus $11K from 47 others

What the payments were for

  • Consulting fees$1,6707%
  • Food & beverage$20,27090%
  • Education$5172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,456 in reported general payments places this provider in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$61,213
Medicare patients
17
Services billed
1,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide83$1,497,808
PomalystPomalidomide48$1,122,791
ImbruvicaIbrutinib36$573,465
TagrissoOsimertinib Mesylate23$387,213
KisqaliRibociclib Succinate21$369,359
Darzalex FasproDaratumumab-Hyaluronidase-Fihj24$320,777
VerzenioAbemaciclib13$202,488
IbrancePalbociclib12$193,908
XtandiEnzalutamide12$150,360
KeytrudaPembrolizumab12$136,511
XgevaDenosumab15$48,259
RetacritEpoetin Alfa-Epbx26$43,660
EliquisApixaban55$33,331
Abiraterone Acetate18$20,159
Imatinib Mesylate30$7,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$193$1,497,80883 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$3,502$1,122,79148 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$24$573,46536 claims
AstraZenecaTagrisso$2,177$387,21323 claims
NovartisKisqali$1,409$369,35921 claims
PfizerIbrance, Retacrit, Eliquis$304$270,89893 claims
Lilly USA, LLCVerzenio$42$202,48813 claims
Astellas Pharma US IncXtandi$174$150,36012 claims
MerckKeytruda$1,115$136,51112 claims
AmgenXgeva$1,680$48,25915 claims
Johnson & JohnsonXarelto$1,418$6,28411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →